YIH
VRDN icon

Y-Intercept (HK)’s Viridian Therapeutics VRDN Stock Holding History

Y-Intercept (HK)’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Buy
+96,756
New +$1.56M 0.04% 774
2026
Q1 		– Sell
-51,151
Closed -$1.59M – 2090
2025
Q4 		$1.59M Sell
51,151
-13,443
-21% -$369K 0.04% 734
2025
Q3 		$1.39M Buy
64,594
+52,414
+430% +$945K 0.03% 814
2025
Q2 		$170K Buy
+12,180
New +$165K ﹤0.01% 1485
2024
Q4 		– Sell
-29,002
Closed -$660K – 1697
2024
Q3 		$660K Buy
+29,002
New +$474K 0.04% 638

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Y-Intercept (HK)'s VRDN Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 96,756 shares worth $1.78M. The stake represents 0.04% of the portfolio and ranks #774 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in VRDN as recently as Q4 2025.

Y-Intercept (HK) first reported a position in VRDN in Q3 2024 and has held it in 5 quarters since. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Y-Intercept (HK) held 96,756 shares of Viridian Therapeutics worth $1.78M as of Q2 2026.
  • Viridian Therapeutics was a new Y-Intercept (HK) position in Q2 2026.
  • Viridian Therapeutics made up 0.04% of Y-Intercept (HK)'s portfolio in Q2 2026, its #774 holding.
  • Y-Intercept (HK) first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.